vs
Apellis Pharmaceuticals, Inc.（APLS）与BRAND HOUSE COLLECTIVE, INC.（TBHC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是BRAND HOUSE COLLECTIVE, INC.的1.9倍（$199.9M vs $103.5M），BRAND HOUSE COLLECTIVE, INC.净利率更高（-3.6% vs -29.5%，领先25.9%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -9.6%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-26.8M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -21.0%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
本公司旗下拥有苏荷馆（Soho House），这是一个面向传媒、艺术与时尚领域从业者的国际私人会员俱乐部，旨在为创意行业从业者提供交流与休闲的专属私密空间。
APLS vs TBHC — 直观对比
营收规模更大
APLS
是对方的1.9倍
$103.5M
营收增速更快
APLS
高出3.6%
-9.6%
净利率更高
TBHC
高出25.9%
-29.5%
自由现金流更多
APLS
多$12.5M
$-26.8M
两年增速更快
APLS
近两年复合增速
-21.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $103.5M |
| 净利润 | $-59.0M | $-3.7M |
| 毛利率 | — | 20.4% |
| 营业利润率 | -25.6% | -1.9% |
| 净利率 | -29.5% | -3.6% |
| 营收同比 | -5.9% | -9.6% |
| 净利润同比 | -62.2% | 51.8% |
| 每股收益（稀释后） | $-0.40 | $-0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSTBHC
| Q4 25 | $199.9M | $103.5M | ||
| Q3 25 | $458.6M | $75.8M | ||
| Q2 25 | $178.5M | $81.5M | ||
| Q1 25 | $166.8M | $148.9M | ||
| Q4 24 | $212.5M | $114.4M | ||
| Q3 24 | $196.8M | $86.3M | ||
| Q2 24 | $199.7M | $91.8M | ||
| Q1 24 | $172.3M | $165.9M |
净利润APLSTBHC
| Q4 25 | $-59.0M | $-3.7M | ||
| Q3 25 | $215.7M | $-20.2M | ||
| Q2 25 | $-42.2M | $-11.8M | ||
| Q1 25 | $-92.2M | $7.9M | ||
| Q4 24 | $-36.4M | $-7.7M | ||
| Q3 24 | $-57.4M | $-14.5M | ||
| Q2 24 | $-37.7M | $-8.8M | ||
| Q1 24 | $-66.4M | $10.1M |
毛利率APLSTBHC
| Q4 25 | — | 20.4% | ||
| Q3 25 | — | 16.3% | ||
| Q2 25 | — | 24.9% | ||
| Q1 25 | — | 30.3% | ||
| Q4 24 | — | 28.1% | ||
| Q3 24 | — | 20.5% | ||
| Q2 24 | — | 29.5% | ||
| Q1 24 | — | 32.0% |
营业利润率APLSTBHC
| Q4 25 | -25.6% | -1.9% | ||
| Q3 25 | 48.7% | -24.7% | ||
| Q2 25 | -18.6% | -12.9% | ||
| Q1 25 | -50.0% | 6.2% | ||
| Q4 24 | -12.3% | -2.1% | ||
| Q3 24 | -24.0% | -15.4% | ||
| Q2 24 | -14.7% | -8.2% | ||
| Q1 24 | -36.0% | 6.4% |
净利率APLSTBHC
| Q4 25 | -29.5% | -3.6% | ||
| Q3 25 | 47.0% | -26.6% | ||
| Q2 25 | -23.6% | -14.5% | ||
| Q1 25 | -55.3% | 5.3% | ||
| Q4 24 | -17.1% | -6.7% | ||
| Q3 24 | -29.2% | -16.8% | ||
| Q2 24 | -18.9% | -9.6% | ||
| Q1 24 | -38.5% | 6.1% |
每股收益（稀释后）APLSTBHC
| Q4 25 | $-0.40 | $-0.16 | ||
| Q3 25 | $1.67 | $-0.90 | ||
| Q2 25 | $-0.33 | $-0.54 | ||
| Q1 25 | $-0.74 | $0.61 | ||
| Q4 24 | $-0.30 | $-0.59 | ||
| Q3 24 | $-0.46 | $-1.11 | ||
| Q2 24 | $-0.30 | $-0.68 | ||
| Q1 24 | $-0.54 | $0.80 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $6.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $-44.0M |
| 总资产 | $1.1B | $229.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSTBHC
| Q4 25 | $466.2M | $6.5M | ||
| Q3 25 | $479.2M | $3.6M | ||
| Q2 25 | $370.0M | $3.5M | ||
| Q1 25 | $358.4M | $3.8M | ||
| Q4 24 | $411.3M | $6.8M | ||
| Q3 24 | $396.9M | $4.5M | ||
| Q2 24 | $360.1M | $3.8M | ||
| Q1 24 | $325.9M | $3.8M |
总债务APLSTBHC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.0M | ||
| Q4 24 | — | $85.8M | ||
| Q3 24 | — | $61.4M | ||
| Q2 24 | — | $47.5M | ||
| Q1 24 | $93.1M | $34.0M |
股东权益APLSTBHC
| Q4 25 | $370.1M | $-44.0M | ||
| Q3 25 | $401.2M | $-35.2M | ||
| Q2 25 | $156.3M | $-16.2M | ||
| Q1 25 | $164.2M | $-19.0M | ||
| Q4 24 | $228.5M | $-27.1M | ||
| Q3 24 | $237.1M | $-19.7M | ||
| Q2 24 | $264.3M | $-5.5M | ||
| Q1 24 | $266.7M | $3.1M |
总资产APLSTBHC
| Q4 25 | $1.1B | $229.2M | ||
| Q3 25 | $1.1B | $221.9M | ||
| Q2 25 | $821.4M | $225.4M | ||
| Q1 25 | $807.3M | $242.2M | ||
| Q4 24 | $885.1M | $279.8M | ||
| Q3 24 | $901.9M | $266.2M | ||
| Q2 24 | $904.5M | $242.6M | ||
| Q1 24 | $831.9M | $250.6M |
负债/权益比APLSTBHC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | 10.88× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-25.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-26.8M |
| 自由现金流率自由现金流/营收 | -7.1% | -25.9% |
| 资本支出强度资本支出/营收 | 0.1% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-18.9M |
8季度趋势，按日历期对齐
经营现金流APLSTBHC
| Q4 25 | $-14.2M | $-25.9M | ||
| Q3 25 | $108.5M | $-7.0M | ||
| Q2 25 | $4.4M | $-3.1M | ||
| Q1 25 | $-53.4M | $19.8M | ||
| Q4 24 | $19.4M | $-12.6M | ||
| Q3 24 | $34.1M | $-12.7M | ||
| Q2 24 | $-8.3M | $-13.7M | ||
| Q1 24 | $-133.0M | $28.2M |
自由现金流APLSTBHC
| Q4 25 | $-14.3M | $-26.8M | ||
| Q3 25 | $108.3M | $-7.4M | ||
| Q2 25 | $4.4M | $-3.6M | ||
| Q1 25 | $-53.4M | $19.0M | ||
| Q4 24 | $19.3M | $-13.1M | ||
| Q3 24 | — | $-13.2M | ||
| Q2 24 | $-8.4M | $-14.4M | ||
| Q1 24 | $-133.3M | $26.7M |
自由现金流率APLSTBHC
| Q4 25 | -7.1% | -25.9% | ||
| Q3 25 | 23.6% | -9.8% | ||
| Q2 25 | 2.5% | -4.5% | ||
| Q1 25 | -32.0% | 12.8% | ||
| Q4 24 | 9.1% | -11.5% | ||
| Q3 24 | — | -15.2% | ||
| Q2 24 | -4.2% | -15.7% | ||
| Q1 24 | -77.3% | 16.1% |
资本支出强度APLSTBHC
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.0% | 0.5% | ||
| Q2 24 | 0.0% | 0.8% | ||
| Q1 24 | 0.2% | 0.9% |
现金转化率APLSTBHC
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.51× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.79× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
TBHC
暂无分部数据
